Skip to main content
. 2024 Nov 25;68:e240422. doi: 10.20945/2359-4292-2024-0422

Table 5. Categorical weight loss with weekly tirzepatide 10 mg or 15 mg in the SURMOUNT series of studies, according to the percentage of weight lost.

Study/duration Population Loss > 5% Loss > 10% Loss > 15% Loss > 20%
SURMOUNT-1 (72 weeks) (161) Individuals with overweight or obesity and without T2DM 90.9%* 83.5%* 70.6%* 56.7%*
SURMOUNT-2 (72 weeks) (167) Individuals with T2DM, with BMI > 27 kg/m2 and HbA1c between 7.0% and 10% 79/83%** 61/65%** 40/48%** 22/31%**
SURMOUNT-3 (72 weeks) (168) Same as SURMOUNT-1; after 12 weeks, patients who achieved > 5% weight reduction with intensive lifestyle change were randomized to placebo or tirzepatide 87.5% 76.7% 65.4% 44.7%
SURMOUNT-4 (36 weeks open-label + 52 weeks) (169) Same as SURMOUNT-1; after 36 weeks, patients on tirzepatide 10 mg or 15 mg were randomized to placebo or tirzepatide 97.3% 92.1% 84.1% 69.5%

* Tirzepatide 15 mg/week.

** Tirzepatide 10 mg/15 mg.